Michael Injaychock joined Eli Lilly in 2007 after five years in a Washington-based financial services consulting role and a subsequent MBA from the University of North Carolina.
Michael Injaychock joined Eli Lilly in 2007 after five years in a Washington-based financial services consulting role and a subsequent MBA from the University of North Carolina. Course work there as well as a stiff self-evaluation of his former job led Injaychock to conclude his future lay in a post that carried a larger purpose. “I captured my ideal position in three words: marketing that matters.”
That desire was reinforced by an early personal experience in the power of modern medicine. “Just after I finished my undergraduate course at the College of William and Mary, my grandfather suffered a severe stroke. The right drug administered at the right time saved his life. My grandfather lived another ten quality years, long enough for me to name my daughter after my grandmother. That real-life testimonial about the value of medicines is better than any marketing message, which is what attracted me to a career in pharmaceuticals.”
Michael Injaychock
Injaychock interviewed with a number of drugmakers but chose Lilly due to the company’s emphasis on the long-term opportunities for leadership. “I liked that my discussions with Lilly focused on personal and professional growth, not just the job.” He quickly advanced to a brand leader role in the diabetes franchise at HQ in Indianapolis, where he helped rejuvenate the aging genetically engineered insulin product, Humulin. While few saw opportunities in the business, he set out to re-launch the franchise, using a tailored pricing strategy and reserving his limited marketing investments around targeted niche segments to improve share of voice in areas where the product still made a difference for endocrinologists and patients.
His work caught the eye of Lilly’s chief marketing officer, who was looking for a candidate to more deeply understand relationships with customers in Japan, the company’s second largest market outside the US, through modern, insights-based market research. Among other things, Lilly had an active portfolio of relatively new products in Japan but little was known about how the changing role of the traditionally all-important physician was affecting the product life cycle-were Lilly’s messages about its medicines actually getting through? Could new technology platforms make a difference as the local customer base evolved? A stronger hand on the market research function would go far in helping affiliate management answer these basic questions.
For the rest of this article and more on this year’s Emering Pharma Leaders, click here.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.